Certified by Founder Lodge
Omega Funds
United States - Boston, Massachusetts
INVESTOR
1 Disclosed Funding Rounds $60,000,000
58 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world’s most urgent medical needs.
Ω is the last letter of the Gr
| Company | Date | Round | Raised |
|---|---|---|---|
 CatalYm GmbH |
July, 16 ,2024 | Series D | $150,000,000 |
 Beta Bionics |
September, 04 ,2023 | Series D | $100,000,000 |
 Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
 EyeBio |
November, 15 ,2023 | Series A | $65,000,000 |
 Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
 Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Beta Bionics |
September, 04 ,2023 | Series D | $100,000,000 |
 SoniVie Ltd |
January, 17 ,2023 | Series C | $60,000,000 |
 Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| EyeBio |
November, 15 ,2023 | Series A | $65,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| CatalYm GmbH |
July, 16 ,2024 | Series D | $150,000,000 |
| EyeBio |
November, 15 ,2023 | Series A | $65,000,000 |
| Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
 XII Medical |
August, 22 ,2024 | Series B | $45,000,000 |
| Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
| CatalYm GmbH |
July, 16 ,2024 | Series D | $150,000,000 |
| Beta Bionics |
September, 04 ,2023 | Series D | $100,000,000 |
| Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| CatalYm GmbH |
July, 16 ,2024 | Series D | $150,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| EyeBio |
November, 15 ,2023 | Series A | $65,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| XII Medical |
August, 22 ,2024 | Series B | $45,000,000 |
| XII Medical |
August, 22 ,2024 | Series B | $45,000,000 |
| CatalYm GmbH |
July, 16 ,2024 | Series D | $150,000,000 |
| XII Medical |
August, 22 ,2024 | Series B | $45,000,000 |
| Alumis |
March, 07 ,2024 | Series C | $259,000,000 |
 Aviceda Therapeutics |
January, 08 ,2025 | Series C | $207,500,000 |
| CatalYm GmbH |
July, 16 ,2024 | Series D | $150,000,000 |
| CatalYm GmbH |
July, 16 ,2024 | Series D | $150,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
 Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| XII Medical |
August, 22 ,2024 | Series B | $45,000,000 |
| XII Medical |
August, 22 ,2024 | Series B | $45,000,000 |
| XII Medical |
August, 22 ,2024 | Series B | $45,000,000 |
| Aviceda Therapeutics |
January, 08 ,2025 | Series C | $207,500,000 |
| Aviceda Therapeutics |
January, 08 ,2025 | Series C | $207,500,000 |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| CatalYm GmbH |
July, 16 ,2024 | Series D | $150,000,000 |
 Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
 NRG Therapeutics |
September, 09 ,2025 | Series B | $67,835,242 |
| Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
| XII Medical |
August, 22 ,2024 | Series B | $45,000,000 |
| Aviceda Therapeutics |
January, 08 ,2025 | Series C | $207,500,000 |
| Callio Therapeutics |
March, 06 ,2025 | Series A | $187,000,000 |
| Antares Therapeutics |
June, 11 ,2025 | Series A | $117,000,000 |
| NRG Therapeutics |
September, 09 ,2025 | Series B | $67,835,242 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
